WaveMan
WaveMan · Company
AKTS · Aktis Oncology, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AKTS Aktis Oncology (AKTS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002035832
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
81
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $495.5K priced

What the filings say about AKTS

Insiders, 180 days
-$3.2M net sold
3 sellers · 18% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$552.8K
1 notice

Aktis Oncology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Aktis Oncology, Inc. insiders sold a net $3.2M of stock across 68 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Czibere Akos
Chief Medical Officer
SELL
2026-09-24 SECtraded 2026-09-23
5,099
$103.0K
-15.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 8, 2026.
  • The trade is 68.9% of the 7,401 shares held after it.
  • No other insider sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Czibere Akos sold about $103.0K of AKTS under a 10b5-1 plan on Sep 23, 2026; 81 funds added in the latest 13F quarter.
Czibere Akos
Chief Medical Officer
SELL
2026-09-24 SECtraded 2026-09-23
7,401
$155.6K
-15.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 8, 2026.
  • No other insider sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Czibere Akos sold about $155.6K of AKTS under a 10b5-1 plan on Sep 23, 2026; 81 funds added in the latest 13F quarter.
Herrmann Ken
Director
SELL
2026-07-21 SECtraded 2026-07-20
3,506
$86.1K
-33.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 17, 2026.
  • The trade is 259.7% of the 1,350 shares held after it.
  • 2 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Herrmann Ken sold about $86.1K of AKTS on Jul 20, 2026; 2 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
Herrmann Ken
Director
SELL
2026-07-21 SECtraded 2026-07-20
1,350
$33.2K
-33.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 17, 2026.
  • 2 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Herrmann Ken sold about $33.2K of AKTS on Jul 20, 2026; 2 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
Herrmann Ken
Director
SELL
2026-07-20 SECtraded 2026-07-17
3,065
$77.3K
-33.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 2 other insiders sold within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Herrmann Ken sold about $77.3K of AKTS on Jul 17, 2026; 2 other insiders sold within 30 days and 81 funds added in the latest 13F quarter.
68 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 63 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.2M over 180 days
-$258.6K over 90 days
below 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
81 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
+111.4% year over year (latest quarter)
more than 85% of Pharma & Biotech
Margin
-713.5% net margin (latest quarter)
below 81% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
16.5% of the float short (float per yahoo 2026-10-26) · 7.3 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AKTS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.6%12M
-33%-7%+18%+44%2026-012026-022026-042026-062026-072026-092026-10 2026-01-12 · NODELMAN OLEG bought $37.4M2026-01-12 · MPM ONCOLOGY INNOVATIONS FUND LP bought $20.0M2026-01-12 · GADICKE ANSBERT bought $20.0M2026-01-12 · VIDA VENTURES II-A, LLC bought $14.6M2026-01-12 · Kim Helen Susan bought $14.6M2026-01-12 · Foley Todd bought $4.2M2026-01-12 · NODELMAN OLEG bought $2.6M2026-07-08 · Czibere Akos sold $861.7K2026-07-08 · Ron-Bigger Shulamit sold $838.1K2026-07-08 · Ron-Bigger Shulamit sold $428.7K2026-01-12 · VIDA VENTURES II-A, LLC bought $405.8K2026-01-12 · Kim Helen Susan bought $405.8K2026-07-08 · Czibere Akos sold $401.5K2026-09-23 · Czibere Akos sold $155.6K2026-07-08 · Czibere Akos sold $125.5K2026-07-08 · Ron-Bigger Shulamit sold $120.7K2026-09-23 · Czibere Akos sold $103.0K2026-07-20 · Herrmann Ken sold $86.1K2026-07-17 · Herrmann Ken sold $77.3K2026-07-20 · Herrmann Ken sold $33.2K2026-01-20 · EcoR1 Capital, LLC filed a 5%+ stake (9.1%)2026-01-20 · Oleg Nodelman filed a 5%+ stake (9.1%)2026-01-20 · EcoR1 Capital Fund Qualified, L.P. filed a 5%+ stake (8.2%)2026-01-20 · MPM BIOVENTURES 2018, L.P. filed a 5%+ stake (7.4%)2026-01-20 · MPM BIOVENTURES 2018 (B), L.P. filed a 5%+ stake (0.4%)2026-01-20 · MPM BioVentures 2018 GP LLC filed a 5%+ stake (7.8%)2026-01-20 · MPM ASSET MANAGEMENT INVESTORS BV2018 LLC filed a 5%+ stake (0.1%)2026-01-20 · MPM BioVentures 2018 LLC filed a 5%+ stake (7.9%)2026-01-20 · MPM ONCOLOGY INNOVATIONS FUND LP filed a 5%+ stake (1.6%)2026-01-20 · MPM Oncology Innovations Fund GP LLC filed a 5%+ stake (1.6%)2026-01-20 · Oncology Impact Private Investment Fund 2, L.P. filed a 5%+ stake (9.1%)2026-01-20 · MPM Oncology Investments 2 LLC filed a 5%+ stake (9.1%)2026-01-20 · MPM ASSET MANAGEMENT LLC filed a 5%+ stake (0.6%)2026-01-20 · ANSBERT GADICKE filed a 5%+ stake (19.3%)2026-01-20 · LUKE EVNIN filed a 5%+ stake (9.5%)2026-01-20 · Todd Foley filed a 5%+ stake (8.0%)2026-01-15 · Eli Lilly and Company filed a 5%+ stake (11.9%)2026-09-23 · Akos Czibere filed to sell $552.8K2026-07-20 · KEN HERRMANN filed to sell $119.3K2026-07-17 · KEN HERRMANN filed to sell $77.3K2026-07-08 · SHULAMIT RON-BIGGER filed to sell $1.4M2026-07-08 · AKOS CZIBERE filed to sell $1.4M
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AKTS: institutional holders (13F)

13F holdings, latest reported quarter
MPM BIOIMPACT LLC
4,835,872 sh
$155.9M
EcoR1 Capital, LLC
4,824,469 sh
$155.5M
Blue Owl Capital Holdings LP
3,070,219 sh
$99.0M
BlackRock, Inc.
2,278,358 sh
$73.4M
WELLINGTON MANAGEMENT GROUP LLP
1,966,244 sh
$63.4M

Congress trades in AKTS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
EcoR1 Capital, LLC
Activist 13D · 2026-01-20
9.1%
Oleg Nodelman
Activist 13D · 2026-01-20
9.1%
EcoR1 Capital Fund Qualified, L.P.
Activist 13D · 2026-01-20
8.2%
MPM BIOVENTURES 2018, L.P.
Activist 13D · 2026-01-20
7.4%
MPM BIOVENTURES 2018 (B), L.P.
Activist 13D · 2026-01-20
0.4%

AKTS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Akos Czibere
Filed 2026-09-23
$552.8K
KEN HERRMANN
Filed 2026-07-20
$119.3K
KEN HERRMANN
Filed 2026-07-17
$77.3K
SHULAMIT RON-BIGGER
Filed 2026-07-08
$1.4M
AKOS CZIBERE
Filed 2026-07-08
$1.4M

AKTS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Meridian Small Cap Growth Fund
$3.4M position · as of 2026-06-30
1.2%
Eventide Healthcare & Life Sciences Fund
$16.3M position · as of 2026-06-30
0.9%
Virtus Biotech Clinical Trials Etf
$312.8K position · as of 2026-07-31
0.7%
Polen 5Perspectives Small Growth Fund
$327.8K position · as of 2026-07-31
0.5%
T. Rowe Price Small-Cap Stock Fund, Inc.
$21.8M position · as of 2026-06-30
0.2%
T. Rowe Price Institutional Small-Cap Stock Fund
$11.6M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
3 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.2M sold by insiders over 180 days, 81 funds added last quarter, $552.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AKTS financials

Revenue growth
+111.4%
XBRL, annual
Net margin
-713.5%

AKTS Stock Sonar score 4/7 axes

Find similar shapesCompare

AKTS ranks highest on growth (85th percentile) and institutional and government (60th), and lowest on insider conviction (12th), among Pharma & Biotech peers.

Growth
85
Inputs
  • Revenue growth, YoY+111.4% · 85 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
12
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.0M · 24 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
60
Inputs
  • Funds adding, latest quarter81 · 60 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
22
Inputs
  • Short interest, % of float+16.5% · 22 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Financial health, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AKTS filings, in plain words

Are Aktis Oncology insiders buying or selling AKTS?

In the 180 days to 2026-10-28, Aktis Oncology insiders were net sellers, a net $3.2M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of AKTS?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $552.8K of stock; the latest, by Akos Czibere, was filed 2026-09-23.

Read the full summary

In the 180 days to 2026-10-28, Aktis Oncology insiders were net sellers of AKTS, a net $3.2M across purchases and sales reported on Form 4 by 3 sellers. 18% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $552.8K of stock. The latest 5% ownership filing is a 13D by EcoR1 Capital, LLC, filed 2026-01-20, for 9.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies